Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.76 |
| ▸ | DRD2 | P14416 | 3/20 | 0.76 |
| ▸ | HTR2A | P28223 | 3/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | DRD4 | P21917 | 1/20 | 0.76 |
| ▸ | ACHE | P22303 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | HTR2C | P28335 | 1/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.76 |
| ▸ | CCKBR | P32239 | 1/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.76 |
| ▸ | HRH1 | P35367 | 1/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.76 |
| ▸ | DRD3 | P35462 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL718326 | 0.92 | DRD2 (0.69) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| Hydrochloric Acid SCHEMBL7973986 | 0.92 | HTR1A (0.69) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| Fumaric Acid SCHEMBL1545209 | 0.92 | ABCB11 (0.74) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| Fumaric Acid SCHEMBL1545268 | 0.92 | ABCB11 (0.74) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| Methyl Alcohol SCHEMBL718775 | 0.91 | HTR1A (0.71) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| Methyl Alcohol SCHEMBL142049 | 0.91 | ABCB11 (0.66) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| Methane SCHEMBL7348385 | 0.89 | HTR1A (0.65) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL8346535 | 0.88 | HTR1A (0.77) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| SCHEMBL1545822 | 0.88 | HTR1A (0.72) | HTR1ADRD2HTR2AABCB11CHRM2 | |
| Hydrochloric Acid SCHEMBL7775099 | 0.88 | HTR1A (0.70) | HTR1ADRD2HTR2AABCB11CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458507-B1 | Antipsychotic treatment based on SNP genotype | VANDA PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | claimed |
| US-20160265060-A1 | ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE | VANDA PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | claimed |
| US-9328387-B2 | Antipsychotic treatment based on SNP genotype | VANDA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20100292211-A1 | ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE | VANDA PHARMACEUTICALS, INC. | 2010-11-18 | — | — | US | claimed |
| US-20100249188-A1 | PREDICTION OF QT PROLONGATION BASED ON SNP GENOTYPE | VANDA PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | claimed |
| US-20160166561-A1 | ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE | VANDA PHARMACEUTICALS, INC. | 2016-06-16 | — | — | US | disclosed |
| US-9328387-B2 | Antipsychotic treatment based on SNP genotype | VANDA PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9243295-B2 | Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype | Vanda Pharmaceutical, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9057104-B2 | Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype | VANDA PHARMACEUTICALS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2430183-B1 | ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE | VANDA PHARMACEUTICALS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8652776-B2 | Prediction of QT prolongation based on SNP genotype | VANDA PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8198305-B2 | 1-(4-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)-3-methoxy-d3-phenyl)ethanone substituted with deuterium ions; antipsycholtic agent | CONCERT PHARMACEUTICALS INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-2430183-A1 | ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE | Vanda Pharmaceuticals Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120053207-A1 | ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE | VANDA PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20100292211-A1 | ANTIPSYCHOTIC TREATMENT BASED ON SNP GENOTYPE | VANDA PHARMACEUTICALS, INC. | 2010-11-18 | — | — | US | disclosed |
| WO-2010132866-A1 | ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE | VANDA PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100249188-A1 | PREDICTION OF QT PROLONGATION BASED ON SNP GENOTYPE | VANDA PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2008128166-A1 | DEUTERATED DERIVATIVES OF 4-(6-FLUORO-1, 2-BENZISOXAZOL-3-YL) PIPERIDINE COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255194-A1 | 1,2-Benzisoxazol-3-yl Compounds | CONCERT PHARMACEUTICALS INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255194-A1 | 1,2-Benzisoxazol-3-yl Compounds | HTR5A, HTR1A, HTR3A | HTR1A 2/4885DRD2 29/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.